Read by QxMD icon Read

Future Oncology

Robert S Miller, Jennifer L Wong
No abstract text is available yet for this article.
October 20, 2017: Future Oncology
Andrew J Yee, Noopur S Raje
Bone is a common site for malignant involvement, either as a site of metastasis, especially in breast or prostate cancer, or as a defining characteristic of the disease, as in multiple myeloma. Bone disease is a major source of morbidity, and half of patients with bone involvement develop skeletal-related events such as pathological fractures or cord compression requiring surgery and/or radiation. Skeletal involvement also increases mortality, as pathologic fractures increase the risk of dying by 20-40%. Osteoclast inhibition with bisphosphonates such as zoledronic acid and recently denosumab has been a significant improvement for bone disease...
October 20, 2017: Future Oncology
Shweta Lawania, Navneet Singh, Digamber Behera, Siddharth Sharma
AIM: The study investigated role of xeroderma pigmentosum complementation group D (XPD) single nucleotide polymorphisms in modulating lung cancer risk and its association with overall survival and clinical outcomes. METHODS:  XPD polymorphisms were detected using Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP). RESULTS:  CC genotype of A751C polymorphism was associated with an increased lung cancer risk (p = 0...
October 16, 2017: Future Oncology
Andrés Poveda, Christian Marth
Although platinum-based chemotherapy continues to be the first-line option for advanced ovarian cancer and for platinum recurrences beyond 6 months, platinum rechallenge is not the best approach for some patients, such as those with residual toxicities, platinum-related hypersensitivity reactions or limited platinum-sensitivity (i.e., a platinum treatment-free interval [TFIp] of 6-12 months). Results of the MITO-8 study called into question the role of single-agent nonplatinum-based regimens in this specific subset of ovarian cancer patients...
October 11, 2017: Future Oncology
Isabelle Ray-Coquard
Trabectedin presents a complex mode of action affecting key cell biology processes in tumor cells and in the tumor microenvironment. In ovarian cancer patients with a platinum treatment-free interval of 6-12 months treated with trabectedin + pegylated liposomal doxorubicin (PLD) or single-agent PLD, and retreated with platinum after relapse, overall survival was significantly prolonged in the trabectedin + PLD group. Mechanisms by which trabectedin restores tumor sensitivity to platinum include its interaction with components of the nucleotide excision repair machinery in tumor cells and inhibition of inflammatory mediators such as IL-6 in the tumor microenvironment...
October 11, 2017: Future Oncology
Nicoletta Colombo
Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells...
October 11, 2017: Future Oncology
Andrés Poveda, Christian Marth
No abstract text is available yet for this article.
October 11, 2017: Future Oncology
Antonio González-Martín
The outcome of the 5th Ovarian Cancer Consensus Conference (OCCC) held in November 2015 in Tokyo, Japan, was the development of new and revised consensus statements to guide clinical investigations in ovarian cancer. The OCCC statements may also have direct application to daily clinical practice. This review examines the consensus statements for recurrent ovarian cancer and their impact on treatment paradigms. Importantly, patients are no longer to be categorized by the platinum-free interval (with its arbitrary 6-month cut-off points) but according to the question: 'is platinum still an option for the patient?' Another important change since the 4th OCCC in 2010 is the inclusion of BRCA mutation status when defining patient subgroups for entry into clinical trials...
October 11, 2017: Future Oncology
Ryan Phillips, Piet Ost, Phuoc T Tran
No abstract text is available yet for this article.
October 11, 2017: Future Oncology
Inês Faleiro, Joana Dias Apolónio, Aryeh J Price, Ramon Andrade De Mello, Vânia Palma Roberto, Uri Tabori, Pedro Castelo-Branco
AIM: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. MATERIALS & METHODS: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). RESULTS: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis...
October 11, 2017: Future Oncology
Jianxin Chen, Junhui Wang, Xilin Wu, Xiaoling Che, Yan Zou, Meiling Weng, Qian Miao, Qinhong Zheng
AIM: We performed a meta-analysis to evaluate the efficacy and safety for S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer. PATIENTS & METHODS: Eligible randomized clinical trials (RCTs) were included, of which data were extracted by inclusion criteria and exclusion one. Odds ratio and hazard ratio (HR) of outcomes including objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse effects (AEs) were explored for the final analysis...
October 10, 2017: Future Oncology
Giovanni Corso, Irene Feroce, Mattia Intra, Paolo Veronesi, Virgilio Sacchini, Bernardo Bonanni, Viviana Galimberti
No abstract text is available yet for this article.
October 6, 2017: Future Oncology
Vaia Florou, Breelyn A Wilky, Jonathan C Trent
Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations...
October 6, 2017: Future Oncology
Mutlu Hızal, Mehmet An Şendur, Burak Bilgin, Muhammed Bülent Akıncı, Didem Şener Dede, Bulent Yalçın
No abstract text is available yet for this article.
October 6, 2017: Future Oncology
Jian Wang, Shumei Chi, Zhongke Huang, Xiaojuan Ye, Guohua Shi, Dongfang Chen, Cen Lou
AIM: To explore the patterns of gene expression and functionally characterize the differentially expressed genes (DEGs) in thyroid cancer. METHODS: DEGs were determined between 57 paired thyroid cancer and noncancerous tissues using DESeq2. Subsequently, the main functions of the DEGs were studied by a variety of analyses. RESULTS: We identified a cohort of 752 upregulated and 309 downregulated DEGs in thyroid cancer. Several hub DEGs were found in the protein-protein interaction networks...
October 6, 2017: Future Oncology
Rita Bonfiglio, Daniela Nardozi, Manuel Scimeca, Chiara Cerroni, Alessandro Mauriello, Elena Bonanno
No abstract text is available yet for this article.
October 6, 2017: Future Oncology
Susu Zheng, Hujia Shen, Qingan Jia, Chuyu Jing, Jiajia Lin, Meixia Zhang, Xiaolei Zhang, Boheng Zhang, Yinkun Liu
AIM: We explored the expression of S100A6 and its role in intrahepatic cholangiocarcinoma (ICC). METHODS: The expression of S100A6 in ICC samples was detected by immunohistochemistry. In vitro experiments, we silenced and overexpressed S100A6 to investigate its role in cell functions. RESULTS: The expression of S100A6 was markedly increased in ICC tissues and cell lines. S100A6 overexpression was an independent risk factor for patients' survival...
October 6, 2017: Future Oncology
David J Adams
Dr David Adams speaks to Editor of Oncology Central, Jade Parker: Based at Wellcome Trust Sanger Institute as a senior group leader, David Adams uses DNA sequencing of patients and genetic screens in human cells and mice to identify cancer genes and genetic interactions. The Adams group studies the mechanisms of cancer development, particularly skin cancer (melanoma) and colorectal cancer. They sequence DNA from families with a high incidence of cancer and also tumors from patients to understand why some people are at greater risk of tumor development and how cancers evolve...
October 6, 2017: Future Oncology
Navid Sobhani, Silvia Paola Corona, Deborah Bonazza, Anna Ianza, Tania Pivetta, Giandomenico Roviello, Maurizio Cortale, Alessandra Guglielmi, Fabrizio Zanconati, Daniele Generali
Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where asbestos has been used for industrial applications. Notwithstanding the progress made in the field, patients do not survive more than 12 months on average with standard treatment. With the advent of next generation sequencing, it is now possible to study the mutational landscape of each tumor with the aim of identifying the genetic aberrations driving tumorigenesis...
October 6, 2017: Future Oncology
Savio George Barreto, Bhawna Sirohi
No abstract text is available yet for this article.
October 6, 2017: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"